Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15252/embr.202153865 http://scihub22266oqcxt.onion/10.15252/embr.202153865 34927793!8811630!34927793     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EMBO+Rep 2022 ; 23 (2): e53865 Nephropedia Template TP {{tp|p=34927793|t=2022. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern |pdf=|usr=}}{{34927793}} gab.com Text Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern JO: EMBO Rep http://www.kidney.de/pget.php?&tw=1&pmid=34927793 #FOAvip The ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants of concern (VOCs) requires continued development of effective therapeutics. Recently, we identified high-affinity neutralizing nanobodies (Nbs) specific for the receptor-binding domain (RBD) of SARS-CoV-2. Taking advantage of detailed epitope mapping, we generate two biparatopic Nbs (bipNbs) targeting a conserved epitope outside and two different epitopes inside the RBD:ACE2 interface. Both bipNbs bind all currently circulating VOCs with high affinities and are capable to neutralize cellular infection with VOC B.1.351 (Beta) and B.1.617.2 (Delta) in vitro. To assess if the bipNbs NM1267 and NM1268 confer protection against SARS-CoV-2 infection in vivo, human ACE2 transgenic mice are treated intranasally before infection with a lethal dose of SARS-CoV-2 B.1, B.1.351 (Beta) or B.1.617.2 (Delta). Nb-treated mice show significantly reduced disease progression and increased survival rates. Histopathological analyses further reveal a drastically reduced viral load and inflammatory response in lungs. These data suggest that both bipNbs are broadly active against a variety of emerging SARS-CoV-2 VOCs and represent easily applicable drug candidates. Twit Text FOAVip Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern ????EMBO Rep http://www.kidney.de/pget.php?&tw=1&pmid=34927793 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34927793 #FOAvip English Wikipedia <ref>{{Cite pmid|34927793}}</ref> Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern #MMPMID34927793 Wagner TR; Schnepf D; Beer J; Ruetalo N; Klingel K; Kaiser PD; Junker D; Sauter M; Traenkle B; Frecot DI; Becker M; Schneiderhan-Marra N; Ohnemus A; Schwemmle M; Schindler M; Rothbauer U EMBO Rep 2022[Feb]; 23 (2): e53865 PMID34927793show ga The ongoing COVID-19 pandemic and the emergence of new SARS-CoV-2 variants of concern (VOCs) requires continued development of effective therapeutics. Recently, we identified high-affinity neutralizing nanobodies (Nbs) specific for the receptor-binding domain (RBD) of SARS-CoV-2. Taking advantage of detailed epitope mapping, we generate two biparatopic Nbs (bipNbs) targeting a conserved epitope outside and two different epitopes inside the RBD:ACE2 interface. Both bipNbs bind all currently circulating VOCs with high affinities and are capable to neutralize cellular infection with VOC B.1.351 (Beta) and B.1.617.2 (Delta) in vitro. To assess if the bipNbs NM1267 and NM1268 confer protection against SARS-CoV-2 infection in vivo, human ACE2 transgenic mice are treated intranasally before infection with a lethal dose of SARS-CoV-2 B.1, B.1.351 (Beta) or B.1.617.2 (Delta). Nb-treated mice show significantly reduced disease progression and increased survival rates. Histopathological analyses further reveal a drastically reduced viral load and inflammatory response in lungs. These data suggest that both bipNbs are broadly active against a variety of emerging SARS-CoV-2 VOCs and represent easily applicable drug candidates. |*COVID-19[MESH] |*Single-Domain Antibodies/genetics[MESH] |Animals[MESH] |Antibodies, Neutralizing[MESH] |Antibodies, Viral[MESH] |Humans[MESH] |Mice[MESH] |Mice, Transgenic[MESH] |Pandemics[MESH] |SARS-CoV-2[MESH]Biparatopic nanobodies protect mice from lethal challenge with SARS-Co(epmc).pdf DeepDyve Pubget Overpricing